title: Biliary tract infection caused by Vibrio fluvialis in an immunocompromised patient.
authors.forename: W-L
authors.initials: WL
authors.lastname: Liu
authors.forename: Y-H
authors.initials: YH
authors.lastname: Chiu
authors.forename: C-M
authors.initials: CM
authors.lastname: Chao
authors.forename: C-C
authors.initials: CC
authors.lastname: Hou
authors.forename: C-C
authors.initials: CC
authors.lastname: Lai
mesh_terms: D015746:Abdominal Pain / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001653:Bile Ducts, Intrahepatic / Q000187:drug effects / Q000382:microbiology* / Q000473:pathology; D042883:Choledocholithiasis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D003920:Diabetes Mellitus / Q000276:immunology; D003937:Diagnosis, Differential; D005260:Female; D042882:Gallstones / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D006801:Humans; D016867:Immunocompromised Host; D007676:Kidney Failure, Chronic / Q000276:immunology; D008103:Liver Cirrhosis / Q000276:immunology; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D012307:Risk Factors; D013624:Taiwan; D000078142:Tazobactam; D016896:Treatment Outcome; D014733:Vibrio / Q000187:drug effects / Q000302:isolation & purification*; D014735:Vibrio Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D014839:Vomiting / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology
chemical_list: D000900:Anti-Bacterial Agents; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin